Press Release January 11, 2018

Alnylam Pharmaceuticals and Sanofi Enter Into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

The Life Sciences team advised Alnylam Pharmaceuticals, Inc. on its strategic restructuring of its RNAi therapeutics alliance with Sanofi to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global development and commercialization rights to its investigational RNAi therapeutics programs for the treatment of ATTR amyloidosis, including patisiran and ALN-TTRsc02.
 
This restructuring provides Alnylam with the opportunity to consolidate its ATTR amyloidosis business to maximize its value, and the opportunity for near-term acceleration of product revenue growth based on newly obtained rights to commercialize patisiran around the world, once approved. In addition, it enables Alnylam to build a global presence and commercial infrastructure that can be leveraged for ALN-TTRsc02 and additional programs – including givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias, and cemdisiran, an investigational RNAi therapeutic for the treatment of complement-mediated diseases – where Alnylam has retained global ownership.
 
Alnylam Pharmaceuticals is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic and hepatic infectious diseases.
 
The Goodwin team was led by partner Christopher Denn and included partners Kingsley Taft and Daniel Karelitz; counsel Todd Hahn; and associate Melissa Paddock.
 
For additional details on the transaction, please read the press release.